Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPLEMENGO – Immunogenicity and safety of three meningococcal B vaccine strategies in adults with asplenia
2024-513649-35-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2024
- Countries
- 1
01
Overview
Phase 3, randomised trial of meningococcal group B vaccine in meningococcal disease (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary immunogenicity endpoint. Planned start Aug 2024; status: authorised.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2024-513649-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513649-35-00.